Voit, Richard A. http://orcid.org/0000-0002-6790-8641
Tao, Liming
Yu, Fulong http://orcid.org/0000-0002-6100-8300
Cato, Liam D.
Cohen, Blake
Fleming, Travis J.
Antoszewski, Mateusz http://orcid.org/0000-0002-7651-0547
Liao, Xiaotian
Fiorini, Claudia
Nandakumar, Satish K.
Wahlster, Lara
Teichert, Kristian
Regev, Aviv
Sankaran, Vijay G. http://orcid.org/0000-0003-0044-443X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01DK103794, R01 CA265726, R01 HL146500, T32 HL007574, T32 HL007574)
New York Stem Cell Foundation (NYSCF-R-I48)
Edward P. Evans Foundation
Klarman Family Foundation
Howard Hughes Medical Institute
Article History
Received: 22 February 2022
Accepted: 25 October 2022
First Online: 15 December 2022
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until 31 August 2020 was a scientific advisory board member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. Since 1 August 2020, A.R. has been an employee of Genentech, a member of the Roche Group. V.G.S. serves as an advisor to and/or has equity in Branch Biosciences, Ensoma, Novartis, Forma and Cellarity, all unrelated to the present work. The authors have no other competing interests to declare.